The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials

Alzheimer's and Dementia

Volumn 9, Issue 1 SUPPL., 2013, Pages

  Raghavan, Nandini ^a   Samtani, Mahesh N ^a   Farnum, Michael ^b   Yang, Eric ^b   Novak, Gerald ^a   Grundman, Michael ^c   Narayan, Vaibhav ^a   Dibernardo, Allitia ^a  

^a JOHNSON AND JOHNSON   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Global R and D Partners   (United States)

Author keywords

ADAS Cog; Alzheimer's disease; Ceiling effects; Clinical trials; Composite endpoints; MCI; Mild cognitive impairment; Novel endpoints; Power; Sample size

Indexed keywords

AMYLOID BETA PROTEIN[1-42];

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE; ARTICLE; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PRIORITY JOURNAL; SCORING SYSTEM;

AGED; ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS;

EID: 84873411466     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.05.2187     Document Type: Article

References (36)

1. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, and M. Raskind A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
2. E.R. Siemers, S. Friedrich, R.A. Dean, C.R. Gonzales, M.R. Farlow, and S.M. Paul Safety and changes in plasma and cerebrospinal fluid amyloid β after a single administration of an amyloid β monoclonal antibody in subjects with Alzheimer disease Clin Neuropharmacol 33 2010 67 73
3. S. Ostrowitzki, D. Deptula, L. Thurfjell, F. Barkhof, B. Bohrmann, and D.J. Brooks Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab Arch Neurol 69 2011 198 207
4. W.G. Rosen, R.C. Mohs, and K.L. Davis A new rating scale for Alzheimer's disease Am J Psychiatry 141 1984 1356 1364
5. R.C. Mohs, D. Knopman, R.C. Petersen, S.H. Ferris, C. Ernesto, and M. Grundman Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope: the Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 1997 S13 S21
6. J. Birks Cholinesterase inhibitors for Alzheimer's disease Cochrane Database Syst Rev 25 2006 CD005593
7. M.N. Samtani, M. Farnum, V. Lobanov, E. Yang, N. Raghavan, and A. DiBernardo An improved model for disease progression in subjects from Alzheimer's Disease Neuroimaging Initiative J Clin Pharmacol 52 2012 629 644
8. P.M. Doraiswamy, L. Kaiser, F. Bieber, and R.L. Garman The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease Alzheimer Dis Assoc Disord 15 2001 174 183
9. M.N. Samtani, N. Raghavan, Y. Shi, G. Novak, M. Farnum, and Lobanov V. Disease progression model in MCI subjects from Alzheimer's Disease Neuroimaging Initiative: CSF biomarkers predict population subtypes Br J Clin Pharmacol 2012 doi: 10.1111/j.1365-2125.2012.04308.x
10. S.J. Cano, H.B. Posner, M.L. Moline, S.W. Hurt, J. Swartz, and T. Hsu The ADAS-Cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts J Neurol Neurosurg Psychiatry 81 2010 1363 1368
11. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, and K.L. Davis Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial JAMA 289 2003 2819 2826
12. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, and N.C. Fox Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 2005 1553 1562
13. Leber P. Guidelines for the clinical evaluation of antidementia drugs. First draft. Food and Drug Administration, 1990.
14. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. In: European Medicines Agency (EMEA) Pre-Authorisation Evaluation of Medicines for Human Use. Doc. ref. CPMP/EWP/553/95 Rev. 1. London, UK: 2008.
15. M. Grundman, R.C. Petersen, D.A. Bennett, H.H. Feldman, S. Salloway, and P.J. Visser Alzheimer's Association Research roundtable meeting on mild cognitive impairment: what have we learned? Alzheimer Dement 2 2006 220 233
16. Available at: The Alzheimer's Disease Neuroimaging Initiaitve (ADNI), http://adni.loni.ucla.edu/about-data-samples. Accessed November 10, 2010.
17. Available at: The Alzheimer's Disease Neuroimaging Initiaitve (ADNI), http://adni.loni.ucla.edu/about-data-samples. Accessed November 10, 2010.
18. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects Ann Neurol 65 2009 403 413
19. ADNI General Procedures Manual. Available at: http://adni.loni.ucla.edu/ wp-content/uploads/2010/09/ADNI-GeneralProceduresManual.pdf. Accessed November 4, 2010.
20. R Development Core Team. 2010. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Available at: http://www.R-project.org. Accessed April 13, 2011.
21. M.C. Donohue, A.C. Gamst, R.G. Thomas, L. Beckett, R.C. Petersen, and M.W. Weiner The relative efficiency of time-to-threshold and rate of change in longitudinal data Contemp Clin Trials 32 2011 685 693
22. M.C. Donohue, A.C. Gamst, and P.S. Aisen Correspondence about "Requiring an amyloid biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials." Alzheimer Dement 7 2011 245 246
23. R.C. Petersen, R.G. Thomas, M. Grundman, D. Bennett, R. Doody, and S. Ferris Vitamin E and donepezil for the treatment of mild cognitive impairment N Engl J Med 352 2005 2379 2388
24. M. Grundman, R.C. Petersen, S.H. Ferris, R.G. Thomas, P.S. Aisen, and D.A. Bennett Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials Arch Neurol 61 2004 59 66
25. J.J. Sevigny, Y. Peng, L. Liu, and C.R. Lines Item analysis of ADAS-Cog: effect of baseline cognitive impairment in a clinical AD trial Am J Alzheimer Dis Other Dement 25 2010 119 124
26. M.R. Schoenberg, K.A. Dawson, K. Duff, D. Patton, J.G. Scott, and R.L. Adams Test performance and classification statistics for the Rey Auditory Verbal Learning Test in selected clinical samples Arch Clin Neuropsychol 21 2006 693 703
27. Y. Stern, and D.M. Jacobs Preliminary findings from the predictors study: utility of clinical signs for predicting disease course Alzheimer Dis Assoc Disord 9 1995 S14 S18
28. R.S. Doody, P. Massman, and J.K. Dunn A method for estimating progression rates in Alzheimer disease Arch Neurol 58 2001 449 454
29. R. Doody, V. Pavlik, P. Massman, S. Rountree, E. Darby, and W. Chan Predicting progression in Alzheimer's disease Alzheimer Res Ther 2 2010 2
30. W. Offen, C. Chuang Stein, A. Dmitrienko, G. Littman, J. Maca, and L. Meyerson Multiple co-primary endpoints: medical and statistical solutions: a report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America Drug Info J 41 2007 31 46
31. P.S. Aisen PS, S. Andrieu, C. Sampaio, M. Carrillo, Z.S. Khachaturian, and B. Dubois Report of the task force on designing clinical trials in early (predementia) AD Neurology 76 2011 280 286
32. C.M. Cullum, K. Saine, L. Davis-Chan, K. Martin-Cook, K.F. Gray, and M. Weiner A performance-based instrument to assess functional capacity in dementia: the Texas Functional Living Scale Neuropsychiatr Neuropsychol Behav Neurol 14 2001 103 108
33. R.E. Tractenberg, M.F. Weiner, M.B. Patterson, L. Teri, and L.J. Thal Emergent psychopathology in AD patients over 12 months associated with functional, not cognitive, changes J Geriatr Psychiatry Neurol 15 2002 110 117
34. R.E. Tractenberg, M.F. Weiner, J.L. Cummings, M.B. Patterson, and L.J. Thal Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach J Neuropsychiatry Clin Neurosci 17 2005 51 60
35. J.R. Husted, R.J. Cook, V.T. Farewell, and D.D. Gladman Methods for assessing responsiveness: a critical review and recommendations J Clin Epidemiol 53 2000 459 468
36. N. Coley, S. Andrieu, M. Jaros, M. Weiner, J. Cedarbaum, and B. Vellas Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary end point for Alzheimer's disease trials Alzheimer Dement 7 2011 602 610.e2